

# Munich Cancer Registry



- ▶ Survival
- ▶ Selection Matrix
- ▶ Homepage
- ▶ *Deutsch*

## ICD-10 C37: Thymus cancer

### Incidence and Mortality

Year of diagnosis	1998-2016
Patients	237
Diseases	238
Creation date	08/21/2018
Export date	08/09/2018
Population	4.81 m





Munich Cancer Registry  
Cancer Registry Bavaria - Upper Bavaria Regional Center  
at Klinikum Grosshadern/IBE  
Marchioninstr. 15  
Munich, 81377  
Germany

<https://www.tumorregister-muenchen.de/en>

[https://www.tumorregister-muenchen.de/en/facts/base/bC37\\_\\_E-ICD-10-C37-Thymus-cancer-incidence-and-mortality.pdf](https://www.tumorregister-muenchen.de/en/facts/base/bC37__E-ICD-10-C37-Thymus-cancer-incidence-and-mortality.pdf)

### Index of figures and tables

Fig./Tbl.		Page
1	Annual cases, DCO, mult. malignancies, follow-up / yr	4
2	Incidence by year of diagnosis	7
3	Age distribution parameters by year of diagnosis	8
4	Age distribution by 5-year age group and sex	9
5	Age-specific incidence, DCO rate, proportion malignancies	10
6	Age distribution and age-specific incidence (chart)	11
6a	Age-specific incidence internationally (chart)	12
7	Standardized incidence ratio of further malignancies	13
8a	Map of cancer incidence (WS) by county (chart)	14
8b	Standardized incidence ratio (SIR) by county (chart)	15
9a	Pts incident cohorts and mortality / yr	16
9b	Incidence and mortality by year of diagnosis	17
9c	Cancer-related deaths, death certification available / yr	18
10	Medians of age at death / yr	19
11	Mortality by year of death	21
12	Distribution of age at death	22
13	Age-specific mortality	23
14	Further malignancies in deaths	24
15	Age-specific mortality (first primaries)	26
16	Age-specific mortality (single primaries)	27
17	Age distribution and age-specific mortality (chart)	28
18a	Map of cancer mortality (WS) by county (chart)	29
18b	Standardized mortality ratio (SMR) by county (chart)	30

**Global Statements about the statistics on the Internet –  
Baseline Statistics** (grey button ) , **Survival** (red button )

In these analyses, the clinics and physicians of Upper Bavaria and the city and county of Landshut<sup>#</sup>, with a total of 4.69 million inhabitants, account for the frequency of cancer diseases<sup>##</sup> and the achieved long term results. Additionally, the long term survival evaluated by the Munich Cancer Registry (MCR) is compared with the results of the population-based registry in the USA (SEER), which is useful for checking the consistency of the data on an international level.

In comparing several tables, inconsistent figures may be detected. This is based on the fact that different patient cohorts are included in the base calculation, for example when proportions of multiple tumors or DCO-cases<sup>###</sup> are concerned. In other cases the individual tumor diagnosis is the basis for calculation, for example with incidence.

The foot notes describe the currentness of the data. The baseline statistics and survival data are updated annually. This yearly analysis comprises the Annual Report of the MCR.

Clinics and physicians have access to essentially more detailed data, with which they can check, compare and in the best case optimize their own data and results.

We would be pleased to receive corrections, critique and useful suggestions. Just send an e-mail to [tumor@ibe.med.uni-muenchen.de](mailto:tumor@ibe.med.uni-muenchen.de).

Munich Cancer Registry, August 2018

<sup>#</sup> Base data has been collected since 1998. An increase in new diseases is apparent, which is an effect of two extensions in the MCR catchment area (from a base population of 2.65 million to 4.10 in 2002, and to 4.69 million in 2007).

<sup>##</sup> Due to the high frequency and good prognosis of non-malignant skin cancer (C44), no systematic ascertainment is performed for this diagnosis. C44 is not designated as a primary, but rather as a secondary tumor.

<sup>###</sup> DCO (death certificate only) identifies a cancer case that first becomes available to the MCR through the death certificate.

### ICD-10 codes (ICD-10 2015) used for specifying cancer site

Code	Description
C37	Malignant neoplasm of thymus

## INCIDENCE

Table 1

Cases with invasive cancer by year of diagnosis, proportions of DCO, further malignancies, deaths, and active follow-up (ALL PATIENTS) (incl. DCO)

Year of diagnosis	All cases n	DCO cases n	Prop. DCO %	Prop. at least 1 further malign. prior + synchron. %	Prop. at least 1 further malign. after %	Prop. deaths %	Prop. actively followed %
1998	6			0.0	11.5	50.0	100.0
1999	4			0.0	10.5	50.0	100.0
2000	3			7.7	10.2	100.0	100.0
2001	4	1	25.0	5.9	10.4	75.0	100.0
2002	13			10.0	10.1	76.9	92.3 #
2003	5			8.6	10.2	80.0	100.0
2004	12	1	8.3	8.5	10.0	66.7	91.7
2005	8	1	12.5	9.1	9.0	50.0	87.5
2006	13	1	7.7	8.8	9.4	61.5	84.6
2007	18	1	5.6	8.1	9.6	50.0	66.7 #
2008	20	2	10.0	11.3	8.7	30.0	50.0
2009	25	1	4.0	12.2	8.5	48.0	76.0
2010	14			11.7	7.6	57.1	64.3
2011	15	1	6.7	11.3	5.5	46.7	73.3
2012	20			11.7	6.5	25.0	60.0
2013	16	1	6.3	11.2	5.3	37.5	43.8
2014	18	1	5.6	11.7	4.9	38.9	77.8
2015	14			13.2	4.2	7.1	78.6
2016	10			13.4	0.0		60.0 ##
1998-2016	238	11	4.6	13.4	11.5	44.5	73.1

238 cases diagnosed 1998-2016 are related to a total of 237 patients. Currently, in 54 (22.8 %) of these 237 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 40 / 12 / 2 (16.9 % / 5.1 % / 0.8 %) patients exist having 2 / 3 / 4+ malignancies.

# The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

## Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retrieved from the respective headings.

How to interpret:

In 2014, a subgroup of 18 cases has been diagnosed, of which 11.7 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 4.9 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Table 1a

Cases with invasive cancer by year of diagnosis, proportions of DCO, further malignancies, deaths, and active follow-up (MALES) (incl. DCO)

Year of diagnosis	Males n	Males %	DCO cases n	Prop. DCO %	Prop. at least 1 further malign. prior + synchron. %	Prop. at least 1 further malign. after %	Prop. deaths %	Prop. actively followed %
1998	4	66.7			0.0	13.4	50.0	100.0
1999	3	75.0			0.0	12.2	33.3	100.0
2000	2	66.7			11.1	11.7	100.0	100.0
2001	1	25.0	1	100.0	10.0	11.9	100.0	100.0
2002	9	69.2			15.8	12.0	77.8	88.9 #
2003	4	80.0			13.0	12.0	75.0	100.0
2004	5	41.7			14.3	12.5	80.0	100.0
2005	5	62.5	1	20.0	15.2	11.1	80.0	100.0
2006	9	69.2	1	11.1	14.3	11.7	55.6	77.8
2007	7	38.9			14.3	11.8	57.1	85.7 #
2008	11	55.0	1	9.1	18.3	11.4	36.4	54.5
2009	12	48.0	1	8.3	16.7	10.3	58.3	83.3
2010	5	35.7			15.6	10.7		20.0
2011	7	46.7			15.5	7.8	42.9	85.7
2012	12	60.0			16.7	9.1	33.3	66.7
2013	10	62.5			16.0	6.3	40.0	50.0
2014	15	83.3	1	6.7	15.7	9.1	33.3	73.3
2015	5	35.7			17.5	12.5		60.0
2016	3	30.0			17.8	0.0		33.3 ##
1998-2016	129	54.2	6	4.7	17.8	13.4	46.5	74.4

129 cases diagnosed 1998-2016 are related to a total of 128 patients. Currently, in 36 (28.1 %) of these 128 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 26 / 8 / 2 (20.3 % / 6.3 % / 1.6 %) patients exist having 2 / 3 / 4+ malignancies.

# The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

## Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retrieved from the respective headings.

How to interpret:

In 2014, a subgroup of 15 cases has been diagnosed, of which 15.7 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 9.1 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Table 1b

Cases with invasive cancer by year of diagnosis, proportions of DCO, further malignancies, deaths, and active follow-up (FEMALES) (incl. DCO)

Year of diagnosis	Females n	Females %	DCO cases n	Prop. DCO %	Prop. at least 1 further malign. prior + synchron. %	Prop. at least 1 further malign. after %	Prop. deaths %	Prop. actively followed %
1998	2	33.3			0.0	9.3	50.0	100.0
1999	1	25.0			0.0	8.5	100.0	100.0
2000	1	33.3			0.0	8.6	100.0	100.0
2001	3	75.0			0.0	8.7	66.7	100.0
2002	4	30.8			0.0	7.9	75.0	100.0 #
2003	1	20.0			0.0	8.2	100.0	100.0
2004	7	58.3	1	14.3	0.0	7.3	57.1	85.7
2005	3	37.5			0.0	6.7		66.7
2006	4	30.8			0.0	7.0	75.0	100.0
2007	11	61.1	1	9.1	0.0	7.3	45.5	54.5 #
2008	9	45.0	1	11.1	2.2	5.6	22.2	44.4
2009	13	52.0			6.8	6.5	38.5	69.2
2010	9	64.3			7.4	4.1	88.9	88.9
2011	8	53.3	1	12.5	6.6	2.5	50.0	62.5
2012	8	40.0			6.0	3.0	12.5	50.0
2013	6	37.5	1	16.7	5.6	4.0	33.3	33.3
2014	3	16.7			6.5	0.0	66.7	100.0
2015	9	64.3			7.8	0.0	11.1	88.9
2016	7	70.0			8.3	0.0		71.4 ##
1998-2016	109	45.8	5	4.6	8.3	9.3	42.2	71.6

109 cases diagnosed 1998-2016 are related to a total of 109 patients. Currently, in 18 (16.5 %) of these 109 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 14 / 4 / 0 (12.8 % / 3.7 % / 0.0 %) patients exist having 2 / 3 / 4+ malignancies.

# The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

## Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retrieved from the respective headings.

How to interpret:

In 2014, a subgroup of 3 cases has been diagnosed, of which 6.5 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 0.0 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Table 2

Incidence measures by year of diagnosis including DCO cases  
(with respect to registry area expansion from 2.65 to 4.10 m as of 2002,  
and from 4.10 to 4.81 m as of 2007, respectively)

Year of diagnosis	Males n	Females n	Males Inc. raw	Fem. Inc. raw	Males Inc. WS	Fem. Inc. WS	Males Inc. ES	Fem. Inc. ES	Males Inc. BRD-S	Fem. Inc. BRD-S
1998	4	2	0.4	0.2	0.2	0.1	0.3	0.1	0.4	0.2
1999	3	1	0.3	0.1	0.3	0.0	0.3	0.1	0.3	0.1
2000	2	1	0.2	0.1	0.2	0.0	0.2	0.0	0.2	0.1
2001	1	3	0.1	0.2	0.0	0.1	0.1	0.2	0.1	0.2
2002	9	4	0.5	0.2	0.4	0.1	0.4	0.1	0.5	0.1
2003	4	1	0.2	0.1	0.1	0.0	0.2	0.0	0.2	0.0
2004	5	7	0.3	0.4	0.2	0.2	0.2	0.3	0.3	0.3
2005	5	3	0.3	0.2	0.2	0.1	0.2	0.2	0.3	0.2
2006	9	4	0.5	0.2	0.3	0.1	0.4	0.1	0.5	0.1
2007	7	11	0.3	0.5	0.2	0.3	0.3	0.4	0.3	0.4
2008	11	9	0.5	0.4	0.3	0.2	0.4	0.3	0.5	0.3
2009	12	13	0.5	0.6	0.3	0.3	0.4	0.4	0.5	0.5
2010	5	9	0.2	0.4	0.1	0.2	0.1	0.3	0.2	0.3
2011	7	8	0.3	0.3	0.2	0.2	0.3	0.2	0.3	0.3
2012	12	8	0.5	0.3	0.4	0.2	0.5	0.3	0.5	0.3
2013	10	6	0.4	0.3	0.3	0.1	0.3	0.1	0.4	0.2
2014	15	3	0.6	0.1	0.4	0.1	0.5	0.1	0.6	0.1
2015	5	9	0.2	0.4	0.1	0.2	0.2	0.3	0.2	0.3
2016	3	7	0.1	0.3	0.1	0.1	0.1	0.2	0.1	0.2
1998-2016	129	109	0.4	0.3	0.2	0.2	0.3	0.2	0.3	0.2

The computation of the incidence measures includes all cancers, irrespective of first or subsequent malignancy.

Table 3

Age distribution parameters by year of diagnosis (ALL PATIENTS)  
(incl. DCO)

Year of diagnosis	Cases n	Std.		Min.	Max.	10%	25%	Median		
		Mean	dev.					50%	75%	90%
1998	6	58.9	17.1	31.0	80.7	31.0	50.5	60.9	69.3	80.7
1999	4	52.9	26.9	14.7	72.5	14.7	34.1	62.2	71.7	72.5
2000	3	54.4	30.6	20.0	78.7	20.0	20.0	64.4	78.7	78.7
2001	4	69.4	5.0	63.2	75.3	63.2	65.8	69.6	73.1	75.3
2002	13	61.4	18.4	28.0	92.7	43.6	45.2	67.3	73.3	81.4
2003	5	56.7	13.5	40.7	72.7	40.7	46.0	57.1	66.9	72.7
2004	12	55.2	19.2	20.2	82.1	33.3	36.3	62.3	65.2	78.1
2005	8	56.3	20.9	18.1	82.4	18.1	43.3	62.6	69.1	82.4
2006	13	59.8	15.3	30.8	83.0	44.7	46.6	61.1	71.8	76.5
2007	18	57.4	13.8	33.5	86.4	40.6	45.5	55.4	63.6	78.9
2008	20	62.0	18.3	29.4	87.6	35.0	42.9	65.6	77.7	82.0
2009	25	62.4	15.7	19.5	89.9	45.9	51.9	64.7	74.1	78.5
2010	14	61.3	16.8	39.1	86.2	39.2	42.2	65.8	72.9	84.0
2011	15	63.3	14.7	42.3	84.7	43.1	50.5	62.3	80.4	83.5
2012	20	57.8	17.2	22.4	82.8	37.4	40.2	62.2	67.6	80.8
2013	16	66.0	13.7	29.6	83.5	49.7	59.6	67.9	76.1	82.7
2014	18	63.2	9.9	48.3	79.1	48.4	56.9	66.1	70.5	78.3
2015	14	62.3	12.4	44.9	86.0	50.1	51.0	59.1	70.4	79.4
2016	10	66.3	15.6	40.5	87.3	44.7	49.4	71.6	79.1	83.3
1998-2016	238	61.0	15.8	14.7	92.7	40.0	50.2	63.1	72.7	80.2

Table 3a

Age distribution parameters by year of diagnosis (MALES)  
(incl. DCO)

Year of diagnosis	Cases n	Std.		Min.	Max.	10%	25%	Median		
		Mean	dev.					50%	75%	90%
1998	4	55.1	20.6	31.0	80.7	31.0	40.8	54.3	69.4	80.7
1999	3	46.9	29.5	14.7	72.5	14.7	14.7	53.6	72.5	72.5
2000	2	42.2	31.3	20.0	64.4	20.0	20.0	42.2	64.4	64.4
2001	1	75.3		75.3	75.3	75.3	75.3	75.3	75.3	75.3
2002	9	56.8	16.2	28.0	74.3	28.0	45.2	55.2	72.9	74.3
2003	4	52.6	11.7	40.7	66.9	40.7	43.3	51.5	62.0	66.9
2004	5	55.8	19.9	20.2	65.8	20.2	64.1	64.4	64.5	65.8
2005	5	59.9	24.7	18.1	82.4	18.1	60.9	65.8	72.5	82.4
2006	9	56.6	14.7	30.8	76.5	30.8	46.6	55.7	69.0	76.5
2007	7	61.4	15.3	33.5	78.9	33.5	52.5	62.8	76.9	78.9
2008	11	62.6	17.8	29.4	84.7	41.9	43.8	66.5	78.8	79.4
2009	12	62.8	18.9	19.5	89.9	45.9	50.7	68.3	75.1	78.1
2010	5	69.3	15.3	44.6	86.2	44.6	70.2	70.8	74.9	86.2
2011	7	57.1	13.8	42.3	82.4	42.3	43.9	55.0	64.7	82.4
2012	12	59.6	16.8	22.4	82.8	37.1	53.2	63.4	66.5	80.2
2013	10	61.9	14.0	29.6	76.8	39.7	57.4	65.0	72.5	75.2
2014	15	62.0	10.4	48.3	79.1	48.4	51.3	59.2	70.5	78.3
2015	5	70.7	11.0	58.5	86.0	58.5	62.9	69.1	76.8	86.0
2016	3	65.8	19.5	49.4	87.3	49.4	49.4	60.6	87.3	87.3
1998-2016	129	60.2	16.3	14.7	89.9	37.1	50.5	62.8	72.5	78.9



Table 3b

Age distribution parameters by year of diagnosis (FEMALES)  
(incl. DCO)

Year of diagnosis	Cases n	Mean	Std. dev.	Min. Max.		10% 25%		Median		
				Min.	Max.	10%	25%	50%	75%	90%
1998	2	66.5	3.9	63.8	69.3	63.8	63.8	66.5	69.3	69.3
1999	1	70.9		70.9	70.9	70.9	70.9	70.9	70.9	70.9
2000	1	78.7		78.7	78.7	78.7	78.7	78.7	78.7	78.7
2001	3	67.5	3.9	63.2	71.0	63.2	63.2	68.3	71.0	71.0
2002	4	71.6	21.1	43.6	92.7	43.6	56.2	75.1	87.0	92.7
2003	1	72.7		72.7	72.7	72.7	72.7	72.7	72.7	72.7
2004	7	54.8	20.3	33.3	82.1	33.3	34.5	56.9	78.1	82.1
2005	3	50.3	15.0	34.5	64.3	34.5	34.5	52.2	64.3	64.3
2006	4	67.1	16.1	44.7	83.0	44.7	56.7	70.3	77.4	83.0
2007	11	54.9	12.9	40.6	86.4	44.3	45.3	52.5	61.9	65.1
2008	9	61.3	19.8	31.9	87.6	31.9	41.2	64.7	77.6	87.6
2009	13	62.1	12.7	41.4	81.9	47.9	53.4	59.9	72.9	78.5
2010	9	56.9	16.7	39.1	84.0	39.1	42.2	60.9	65.8	84.0
2011	8	68.7	14.0	43.1	84.7	43.1	61.5	67.7	81.9	84.7
2012	8	55.1	18.5	37.6	81.5	37.6	38.9	50.0	72.1	81.5
2013	6	72.9	10.8	59.5	83.5	59.5	59.8	76.1	82.7	83.5
2014	3	69.3	1.7	68.0	71.2	68.0	68.0	68.5	71.2	71.2
2015	9	57.6	10.9	44.9	79.4	44.9	50.6	55.5	59.8	79.4
2016	7	66.6	15.5	40.5	79.4	40.5	49.0	72.1	79.1	79.4
1998-2016	109	61.9	15.3	31.9	92.7	40.0	50.1	63.8	72.9	81.9

Table 4

Age distribution by 5-year age group and sex for period 2007-2016  
(incl. DCO)


Age at diagnosis Years	Cases n	Males			Females				
		%	Cum.%	n	%	Cum.%	n	%	Cum.%
0-4									
5-9									
10-14									
15-19	1	0.6	0.6	1	1.1	1.1			0.0
20-24	1	0.6	1.2	1	1.1	2.3			0.0
25-29	2	1.2	2.4	2	2.3	4.6			0.0
30-34	2	1.2	3.5	1	1.1	5.7	1	1.2	1.2
35-39	7	4.1	7.6	1	1.1	6.9	6	7.2	8.4
40-44	15	8.8	16.5	5	5.7	12.6	10	12.0	20.5
45-49	11	6.5	22.9	7	8.0	20.7	4	4.8	25.3
50-54	14	8.2	31.2	6	6.9	27.6	8	9.6	34.9
55-59	20	11.8	42.9	10	11.5	39.1	10	12.0	47.0
60-64	20	11.8	54.7	14	16.1	55.2	6	7.2	54.2
65-69	20	11.8	66.5	10	11.5	66.7	10	12.0	66.3
70-74	18	10.6	77.1	10	11.5	78.2	8	9.6	75.9
75-79	21	12.4	89.4	11	12.6	90.8	10	12.0	88.0
80-84	12	7.1	96.5	4	4.6	95.4	8	9.6	97.6
85+	6	3.5	100.0	4	4.6	100.0	2	2.4	100.0
All ages	170	100.0		87	100.0		83	100.0	

Table 5


Age-specific incidence, DCO rate and proportion of all cancers for period 2007-2016

Age at diagnosis Years	Males n	Females n	Males Age- spec. incid.	Females Age- spec. incid.	Males DCO rate n=2 %	Females DCO rate n=4 %	Males	Females
							Prop.all cancers n=113978 %	Prop.all cancers n=112253 %
0- 4								
5- 9								
10-14								
15-19	1		0.1				0.4	
20-24	1		0.1				0.2	
25-29	2		0.1				0.3	
30-34	1	1	0.1	0.1			0.1	0.1
35-39	1	6	0.1	0.4			0.1	0.2
40-44	5	10	0.3	0.6			0.2	0.2
45-49	7	4	0.4	0.2			0.2	0.1
50-54	6	8	0.3	0.5			0.1	0.1
55-59	10	10	0.7	0.7			0.1	0.1
60-64	14	6	1.1	0.5			0.1	0.1
65-69	10	10	0.8	0.8			0.1	0.1
70-74	10	8	0.9	0.6	10.0		0.0	0.1
75-79	10	10	1.3	1.0	10.0	10.0	0.1	0.1
80-84	4	8	0.9	1.1		12.5	0.0	0.1
85+	4	2	1.3	0.3		100.0	0.1	0.0
All ages	86	83			2.3	4.8	0.1	0.1
Incidence								
Raw			0.4	0.4				
WS			0.2	0.2				
ES			0.3	0.3				
BRD-S			0.4	0.3				

The age-specific incidence characterizes the disease risk in a particular age group. The age distribution depends on the patient population frequency in each age group and reflects the tangible clinical picture of everyday patients care (see following chart).



**Figure 6.** Age distribution (males: mean=62.2 yrs, median=63.3 yrs; females: mean=61.4 yrs, median=61.9 yrs) and age-specific incidence.



**Figure 6a.** Age-specific incidence in MCR registry areas compared to SEER (Surveillance, Epidemiology, and End Results, USA).

Reference:  
 Surveillance, Epidemiology, and End Results (SEER) Program SEER\*Stat Database: Incidence - SEER 18 Regs Research Data, released April 2014, based on the November 2013 submission. <http://www.seer.cancer.gov>.

Table 7a

Standardized incidence ratio (SIR, with 95% confidence limits), excess absolute risk (EAR) and DCO rate of further malignancies for period 1998–2016

MALES

Diagnosis	Observed n	Expected n	SIR	CI 95%	CI 95%	EAR	DCO %
C43 Malign. melanoma	3	0.2	14.0	2.9	41.0 #	72.7	
C61 Prostate	6	1.3	4.5	1.6	9.7 #	121.6	
Others, specified	6	0.6	10.1	3.7	22.0 #	141.1	16.7
Not observed	0	2.6	0.0	0.0	1.4	-68.6	
All further malignancies	15	4.8	3.1	1.8	5.2 #	266.8	6.7
Patients		122					
Median age at next malignancy (years)		63.1					
Person-years		383					
Mean observation time (years)		3.1					
Median observation time (years)		1.6					

# The occurrence of further malignancy listed is statistically significant.

Observed further malignancies with count 1 are pooled in category “Others, specified”.

Table 7b

Standardized incidence ratio (SIR, with 95% confidence limits), excess absolute risk (EAR) and DCO rate of further malignancies for period 1998–2016

FEMALES


Diagnosis	Observed n	Expected n	SIR	CI 95%	CI 95%	EAR	DCO %
C33-C34 Lung	2	0.2	8.9	1.1	32.2 #	61.7	
C50 Breast	3	0.9	3.4	0.7	9.9	73.5	
Others, specified	4	0.4	9.1	2.5	23.2 #	123.6	25.0
Not observed	0	1.3	0.0	0.0	2.7	-46.9	
All further malignancies	9	2.9	3.1	1.4	5.9 #	212.0	11.1
Patients		96					
Median age at next malignancy (years)		66.6					
Person-years		288					
Mean observation time (years)		3.0					
Median observation time (years)		1.7					

# The occurrence of further malignancy listed is statistically significant.


Observed further malignancies with count 1 are pooled in category “Others, specified”.



Standardized incidence ratio (SIR) 2007 - 2016: Males



Standardized incidence ratio (SIR) 2007 - 2016: Females



**Figure 8b.** Map of standardized incidence ratio (SIR, incl. DCO cases) by county averaged for period 2007 to 2016. According to their individual SIR values, the counties are displayed in different red and blue hues, being the fine white color attributed to the population overall of 1.0 (males N=86, females N=83).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 66,416 female residents (averaged) in the period from 2007 to 2016 a total of 2 women were identified with newly diagnosed thymus cancer. Therefore, the mean standardized incidence ratio (SIR) for this cancer type in this area can be calculated at 0.86. Though, the value of this parameter may vary with an underlying probability of 99% between 0.04 and 3.99, and is therefore not statistically striking.

## MORTALITY

Table 9a

Annual cohorts: Incident cancers, follow-up status, proportion of DCO, deaths among the annual cohorts and proportion of available death certificates (with respect to registry area expansion from 2.65 to 4.10 m as of 2002, and from 4.10 to 4.81 m as of 2007, respectively)

Year of diagnosis	Incident cases n	Prop. actively followed %	Prop. DCO %	Deaths n	Prop. deaths %	Prop. deaths with death certific. %
1998	6	100.0		3	50.0	100.0
1999	4	100.0		2	50.0	100.0
2000	3	100.0		3	100.0	100.0
2001	4	100.0	25.0	3	75.0	100.0
2002	13	92.3		10	76.9	100.0
2003	5	100.0		4	80.0	100.0
2004	12	91.7	8.3	8	66.7	100.0
2005	8	87.5	12.5	4	50.0	100.0
2006	13	84.6	7.7	8	61.5	100.0
2007	18	66.7	5.6	9	50.0	100.0
2008	20	50.0	10.0	6	30.0	100.0
2009	25	76.0	4.0	12	48.0	100.0
2010	14	64.3		8	57.1	100.0
2011	15	73.3	6.7	7	46.7	100.0
2012	20	60.0		5	25.0	100.0
2013	16	43.8	6.3	6	37.5	100.0
2014	18	77.8	5.6	7	38.9	100.0
2015	14	78.6		1	7.1	100.0
2016	10	60.0				
1998-2016	238	73.1	4.6	106	44.5	100.0



Table 9b

Annual cohorts of incident cancers and deaths, proportion of death certificates and cases deceased within the same year of being diagnosed with cancer (incl. DCO)

(with respect to registry area expansion from 2.65 to 4.10 m as of 2002, and from 4.10 to 4.81 m as of 2007, respectively)

Year of diagnosis/ death	Incident cases n	Deaths n	Prop. deaths with death certific. %	Deaths in same year n	Prop. deaths in same year %
1998	6	1	100.0		
1999	4	1	100.0		
2000	3	2	100.0		
2001	4	3	66.7	1	25.0
2002	13	6	100.0	2	15.4
2003	5	8	100.0		
2004	12	6	100.0	1	8.3
2005	8	2	100.0	1	12.5
2006	13	13	100.0	2	15.4
2007	18	7	100.0	2	11.1
2008	20	7	100.0	3	15.0
2009	25	13	100.0	4	16.0
2010	14	13	100.0	2	14.3
2011	15	11	100.0	2	13.3
2012	20	12	100.0	1	5.0
2013	16	4	100.0	3	18.8
2014	18	15	100.0	1	5.6
2015	14	13	100.0		
2016	10	6	100.0		
1998-2016	238	143	99.3	25	10.5

Table 9c

Annual cohorts of deaths, proportion of cancer-related and non-cancer-related deaths, and cancer recorded on death certificates  
(incl. DCO)

(with respect to registry area expansion from 2.65 to 4.10 m as of 2002,  
and from 4.10 to 4.81 m as of 2007, respectively)

Year of death	Deaths n	Prop. cancer- related %	Prop. non-cancer- related %	Prop. cancer recorded on death certificate %
1998	1	100.0		100.0
1999	1		100.0	
2000	2	50.0	50.0	100.0
2001	3	100.0		100.0
2002	6	50.0	50.0	83.3
2003	8	62.5	37.5	62.5
2004	6	100.0		100.0
2005	2	50.0	50.0	50.0
2006	13	69.2	30.8	76.9
2007	7	85.7	14.3	100.0
2008	7	85.7	14.3	100.0
2009	13	76.9	23.1	76.9
2010	13	53.8	46.2	69.2
2011	11	81.8	18.2	72.7
2012	12	75.0	25.0	83.3
2013	4	75.0	25.0	75.0
2014	15	73.3	26.7	73.3
2015	13	69.2	30.8	69.2
2016	6	33.3	66.7	100.0
1998-2016	143	70.6	29.4	78.9

Table 10a

Medians of age at death according to the grouping in Table 9  
MALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (non-cancer-related) Years	Age at death (according to death certificate) Years
1998	1	66.5	66.5		66.5
1999	1	46.4		46.4	
2000	1	35.1		35.1	35.1
2001	3	61.9	61.9		68.6
2002	3	55.2	21.7	66.0	55.2
2003	4	66.2	55.8	86.0	55.8
2004	6	68.7	68.7		68.7
2005	1	69.2		69.2	
2006	9	62.9	54.4	66.1	60.7
2007	6	69.9	66.4	73.4	69.9
2008	4	78.7	78.7		78.7
2009	7	76.2	69.9	81.5	69.9
2010	7	77.0	76.0	79.5	75.1
2011	5	79.9	66.9	81.3	66.9
2012	6	68.1	68.1	67.5	67.8
2013	3	68.5	68.5		68.5
2014	9	73.5	72.9	78.7	73.2
2015	6	71.8	71.7	85.4	71.7
2016	3	62.6	59.2	66.0	62.6
1998-2016	85	69.3	68.4	73.4	68.5

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 10b

Medians of age at death according to the grouping in Table 9  
FEMALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (non-cancer-related) Years	Age at death (according to death certificate) Years
1998					
1999					
2000	1	71.7	71.7		71.7
2001					
2002	3	66.1	73.8	64.3	73.8
2003	4	73.2	63.2	83.8	63.2
2004					
2005	1	79.0	79.0		79.0
2006	4	77.3	74.4	82.0	74.4
2007	1	75.1	75.1		75.1
2008	3	60.1	58.7	60.1	60.1
2009	6	69.1	65.1	74.0	65.1
2010	6	78.4	66.2	87.1	74.9
2011	6	43.7	43.7		43.6
2012	6	68.7	67.7	69.7	67.7
2013	1	92.3		92.3	
2014	6	79.9	73.0	90.7	69.8
2015	7	73.1	72.4	75.2	72.4
2016	3	69.9	51.7	71.6	69.9
1998–2016	58	72.1	67.2	75.2	67.7

By 2010, life expectancy at birth was 77.5 years for boys and 82.6 years for girls.

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 11a

Mortality measures (cancer-related death) and mortality-incidence-index  
by year of death

## MALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998	1	0.1	0.25	0.1	0.32	0.1	0.29	0.1	0.23
1999									
2000									
2001	3	0.3	3.00	0.2	3.89	0.2	2.93	0.3	2.07
2002	1	0.1	0.11	0.1	0.21	0.1	0.14	0.1	0.16
2003	3	0.2	0.75	0.1	0.69	0.1	0.78	0.2	0.98
2004	6	0.3	1.20	0.2	0.86	0.2	1.12	0.3	1.28
2005									
2006	7	0.4	0.78	0.3	0.90	0.3	0.78	0.4	0.79
2007	5	0.2	0.71	0.1	0.56	0.2	0.58	0.2	0.70
2008	4	0.2	0.40	0.1	0.29	0.1	0.36	0.2	0.49
2009	5	0.2	0.42	0.1	0.33	0.2	0.37	0.2	0.39
2010	4	0.2	0.80	0.1	0.81	0.1	0.87	0.2	1.18
2011	3	0.1	0.43	0.1	0.33	0.1	0.36	0.1	0.46
2012	4	0.2	0.33	0.1	0.27	0.1	0.31	0.2	0.31
2013	3	0.1	0.30	0.1	0.28	0.1	0.30	0.1	0.29
2014	7	0.3	0.47	0.1	0.40	0.2	0.43	0.3	0.45
2015	5	0.2	1.00	0.1	0.89	0.1	0.92	0.2	0.93
2016	1	0.0	0.33	0.0	0.32	0.0	0.36	0.0	0.30
1998-2016	62	0.2	0.48	0.1	0.42	0.1	0.45	0.2	0.50

Table 11b

Mortality measures (cancer-related death) and mortality-incidence-index  
by year of death

## FEMALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998									
1999									
2000	1	0.1	1.00	0.0	1.97	0.1	1.48	0.1	1.03
2001									
2002	2	0.1	0.50	0.0	0.43	0.1	0.46	0.1	0.55
2003	2	0.1	2.00	0.1	2.58	0.1	2.47	0.1	2.11
2004									
2005	1	0.1	0.33	0.0	0.11	0.0	0.18	0.0	0.32
2006	2	0.1	0.50	0.0	0.41	0.1	0.50	0.1	0.63
2007	1	0.0	0.09	0.0	0.04	0.0	0.06	0.0	0.10
2008	2	0.1	0.22	0.1	0.30	0.1	0.30	0.1	0.25
2009	5	0.2	0.38	0.1	0.37	0.2	0.36	0.2	0.38
2010	3	0.1	0.33	0.1	0.25	0.1	0.30	0.1	0.34
2011	6	0.3	0.75	0.2	1.10	0.2	0.98	0.2	0.72
2012	5	0.2	0.63	0.1	0.43	0.1	0.50	0.2	0.52
2013									
2014	4	0.2	1.33	0.1	1.01	0.1	1.10	0.1	1.35
2015	4	0.2	0.44	0.1	0.30	0.1	0.32	0.1	0.36
2016	1	0.0	0.14	0.0	0.18	0.0	0.18	0.0	0.14
1998-2016	39	0.1	0.36	0.1	0.32	0.1	0.34	0.1	0.35

Table 12

Age distribution of age at death (cancer-related) for period 2007-2016  
(incl. multiple malignancies)

Age at death Years	Cases			Males			Females		
	n	%	Cum.%	n	%	Cum.%	n	%	Cum.%
0-4									
5-9									
10-14									
15-19									
20-24									
25-29									
30-34	1	1.4	1.4	1	2.4	2.4			0.0
35-39	0	0.0	1.4			2.4			0.0
40-44	4	5.6	6.9			2.4	4	12.9	12.9
45-49	3	4.2	11.1	2	4.9	7.3	1	3.2	16.1
50-54	6	8.3	19.4	1	2.4	9.8	5	16.1	32.3
55-59	6	8.3	27.8	4	9.8	19.5	2	6.5	38.7
60-64	4	5.6	33.3	3	7.3	26.8	1	3.2	41.9
65-69	16	22.2	55.6	9	22.0	48.8	7	22.6	64.5
70-74	10	13.9	69.4	7	17.1	65.9	3	9.7	74.2
75-79	10	13.9	83.3	7	17.1	82.9	3	9.7	83.9
80-84	8	11.1	94.4	5	12.2	95.1	3	9.7	93.5
85+	4	5.6	100.0	2	4.9	100.0	2	6.5	100.0
All ages	72	100.0		41	100.0		31	100.0	

Table 13

Age-specific mortality (cancer-related) and proportion of all cancers  
for period 2007-2016  
(incl. multiple malignancies)

Age at death Years	Males		Females		Males		Females	
	n	n	Age- spec. mortal.	MI-index	Age- spec. mortal.	MI-index	Prop.all cancers %	Prop.all cancers %
0- 4								
5- 9								
10-14								
15-19								
20-24								
25-29								
30-34	1		0.1	1.00			1.0	
35-39								
40-44		4			0.2	0.40		0.6
45-49	2	1	0.1	0.29	0.1	0.25	0.2	0.1
50-54	1	5	0.1	0.17	0.3	0.63	0.0	0.3
55-59	4	2	0.3	0.40	0.1	0.20	0.1	0.1
60-64	3	1	0.2	0.21	0.1	0.17	0.1	0.0
65-69	9	7	0.8	0.90	0.5	0.70	0.1	0.1
70-74	7	3	0.6	0.70	0.2	0.38	0.1	0.0
75-79	7	3	0.9	0.70	0.3	0.30	0.1	0.0
80-84	5	3	1.1	1.25	0.4	0.38	0.1	0.0
85+	2	2	0.7	0.50	0.3	1.00	0.0	0.0
All ages	41	31					0.1	0.1
Mortality								
Raw			0.2	0.48	0.1	0.37		
WS			0.1	0.38	0.1	0.35		
ES			0.1	0.43	0.1	0.35		
BRD-S			0.2	0.47	0.1	0.35		
PYLL-70								
per 100,000			1.0		1.4			
ES			0.8		1.1			
AYLL-70			9.8		13.5			

Table 14a

Further malignancies in deaths in period 1998-2016  
MALES

Diagnosis	Total n	Total %↓	Pre n	Pre ←%	Syn- chron ±30d n	Syn- chron ±30d ←%	Post n	Post ←%
C09-C10 Oropharynx	1	3.1					1	100.0
C15 Oesophagus	1	3.1					1	100.0
C16 Stomach	1	3.1					1	100.0
C18 Colon	2	6.3	2	100.0				
C19-C20 Rectum	1	3.1					1	100.0
C32 Larynx	2	6.3	1	50.0			1	50.0
C33-C34 Lung	4	12.5	1	25.0			3	75.0
C37 Thymus	1	3.1					1	100.0
C43 Malign. melanoma	2	6.3	1	50.0			1	50.0
C44 Skin others	2	6.3			1	50.0	1	50.0
C61 Prostate	7	21.9	5	71.4			2	28.6
C64 Kidney	2	6.3	1	50.0			1	50.0
C67 Bladder	2	6.3					2	100.0
C70-C72 CNS cancer	1	3.1					1	100.0
C73 Thyroid	1	3.1					1	100.0
C82-C85 NHL	2	6.3			1	50.0	1	50.0
All further malignancies	32	100.0	11	34.4	2	6.3	19	59.4

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a further malignancy.



Table 14b

Further malignancies in deaths in period 1998-2016  
FEMALES

Diagnosis	Total n	Total %↓	Pre n	Pre ←%	Syn- chron ±30d n	Syn- chron ±30d ←%	Post n	Post ←%
C18 Colon	1	11.1	1	100.0				
C22 Liver	1	11.1					1	100.0
C25 Pancreas	2	22.2					2	100.0
C33-C34 Lung	2	22.2					2	100.0
C50 Breast	1	11.1					1	100.0
C73 Thyroid	1	11.1	1	100.0				
C76-C79 CUP	1	11.1	1	100.0				
All further malignancies	9	100.0	3	33.3			6	66.7

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a further malignancy.

Table 15

Age-specific mortality (cancer-related) and proportion of all cancers  
for period 2007-2016  
(**First primaries only** \*)

Age at death Years	Males n	Females n	Males Age- spec. mortal.	MI-index	Females Age- spec. mortal.	MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4								
5- 9								
10-14								
15-19								
20-24								
25-29								
30-34	1		0.1	1.00			1.0	
35-39								
40-44		4			0.2	0.44		0.7
45-49	2	1	0.1	0.33	0.1	0.25	0.2	0.1
50-54	1	5	0.1	0.17	0.3	0.63	0.1	0.3
55-59	4	2	0.3	0.40	0.1	0.25	0.1	0.1
60-64	2	1	0.2	0.18	0.1	0.20	0.0	0.0
65-69	9	6	0.8	1.00	0.5	0.75	0.2	0.1
70-74	6	1	0.5	0.67	0.1	0.20	0.1	0.0
75-79	5	3	0.6	1.00	0.3	0.33	0.1	0.1
80-84	3	3	0.7	3.00	0.4	0.38	0.1	0.1
85+	1	2	0.3	0.33	0.3	1.00	0.0	0.0
All ages	34	28					0.1	0.1
Mortality								
Raw			0.1	0.50	0.1	0.38		
WS			0.1	0.41	0.1	0.36		
ES			0.1	0.44	0.1	0.37		
BRD-S			0.1	0.50	0.1	0.36		
PYLL-70								
per 100,000			0.9		1.3			
ES			0.8		1.1			
AYLL-70			9.9		14.1			


\* See corresponding tables with multiple malignancies.

Table 16

Age-specific mortality (cancer-related) and proportion of all cancers  
for period 2007-2016  
(**Single primaries only** \*)

Age at death Years	Males n	Females n	Males Age- spec. mortal.	Males MI-index	Females Age- spec. mortal.	Females MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4								
5- 9								
10-14								
15-19								
20-24								
25-29								
30-34	1		0.1	1.00			1.0	
35-39								
40-44		4			0.2	0.44		0.7
45-49	1	1	0.1	0.17	0.1	0.25	0.1	0.1
50-54	1	5	0.1	0.17	0.3	0.63	0.1	0.3
55-59	4	2	0.3	0.40	0.1	0.29	0.1	0.1
60-64	1	1	0.1	0.10	0.1	0.20	0.0	0.0
65-69	7	4	0.6	0.88	0.3	0.67	0.1	0.1
70-74	5	1	0.5	0.71	0.1	0.20	0.1	0.0
75-79	4	2	0.5	1.00	0.2	0.22	0.1	0.0
80-84	1	2	0.2	1.00	0.3	0.29	0.0	0.0
85+	1	1	0.3	0.50	0.1	0.50	0.0	0.0
All ages	26	23					0.1	0.1
Mortality								
Raw			0.1	0.42	0.1	0.33		
WS			0.1	0.34	0.1	0.33		
ES			0.1	0.38	0.1	0.34		
BRD-S			0.1	0.41	0.1	0.32		
PYLL-70								
per 100,000			0.8		1.3			
ES			0.7		1.1			
AYLL-70			10.2		15.4			


\* See corresponding tables with multiple malignancies.




**Figure 17.** Distribution of age at death (bars; males: mean=63.1 yrs, median=67.8 yrs; females: mean=60.2 yrs, median=60.5 yrs) and age-specific mortality (all patients: solid line, patients with single primaries: dotted line). The age-specific incidence is additionally plotted for comparison (dashed line).

The difference between age at diagnosis (Table 3) and age at thymus cancer-related death (see Table 10) should be considered.

Average mortality (world standard population) 2007 - 2016: Males




Average mortality (world standard population) 2007 - 2016: Females




**Figure 18a.** Map of cancer mortality (world standard population) by county averaged for period 2007 to 2016. According to their individual mortality rates, the counties are displayed in different red and blue hues, being the fine white color attributed to the population mean (males 0.1/100,000 WS N=41, females 0.1/100,000 WS N=31).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 66,416 female residents (averaged) in the period from 2007 to 2016 a total of 1 women died from thymus cancer. Therefore, the mean mortality rate for this cancer type in this area can be calculated at 0.0/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.0 and 1.0/100,000.

Standardized mortality ratio (SMR) 2007 - 2016: Males



Standardized mortality ratio (SMR) 2007 - 2016: Females



**Figure 18b.** Map of standardized mortality ratio (SMR, incl. DCO cases) by county averaged for period 2007 to 2016. According to their individual SMR values, the counties are displayed in different red and blue hues, being the fine white color attributed to the population overall of 1.0 (males N=41, females N=31).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 66,416 female residents (averaged) in the period from 2007 to 2016 a total of 1 women died from thymus cancer. Therefore, the mean standardized mortality ratio (SMR) for this cancer type in this area can be calculated at 1.16. Though, the value of this parameter may vary with an underlying probability of 99% between 0.01 and 8.58, and is therefore not statistically striking.

### Statistical Notes

In all tables and figures the respective reference values should be carefully considered. The incidence rates include diagnoses (with multiple primary), and death certificate only (DCO) cases, where applicable. For mortality statistics patients, diagnoses and progressive course of disease are presented. In the calculations, all courses of disease are considered whereby progressions occurred and/or death certificate identified progressive cancers were ascertained. Additionally there are three groups of disease course to consider:

#### 1. All multiple primaries included

The mortality statistic describes the tumor-specific death, independent of any malignancy. The patient perspective, induced secondary malignancies, and the problem of multiple malignancies from the same primary tumor all have reasons for their inclusion.

#### 2. First singular primary (no information about other prior or synchronous malignancy)

The mortality statistic describes the cancer-related death for patients who have no therapeutic restrictions due to a previous or synchronous cancer. These statistics are comparable to studies that have exclusion criteria based on a second malignancy.

#### 3. Single primary (no information about other prior, syn- or metachronous malignancy)

The mortality statistic describes the tumor-specific death that occurs without any impact through secondary primaries, earlier, synchronous, later or induced. Precisely the difference between disease group 1 and 2 highlight the magnitude of the problem of secondary malignancies.

For this reason differences appear concerning official mono-causal mortality statistics. To judge the maximum deviation, 2 further tables are presented. In the first table the distribution of secondary malignancies before, at or after the described cancer are shown, that could be an alternative cause of death. In the second table, the age-specific mortality rates for all courses of disease, without designation of secondary malignancies are shown.

A previously minimally acknowledged statistic is the **age at death**, which allows for a good assessment of the quality of classification of the apparent tumor-specific death. For assumed tumor-independent deaths, the age of death should be estimated from the age of diagnosis and the normal life expectancy, whereas tumor-dependent deaths can be estimated from the age of diagnosis plus the average tumor-specific life expectancy. The comparison of different tumors demonstrates this association, if the causes of cancer and the competing cause of death are independent of each other (e.g. breast and colon versus head/neck and lung).

The index from mortality and incidence (Mortality-Incidence ratio, **MI-index**) is a statistic that allows for the evaluation of the quality of data. For diseases with poor prognoses, comparable values are obtained from all age groups, because to a large extent, the numerator and denominator contain the same cases. For tumors with a good prognosis, increasing and decreasing incidence and age-specific differences in prognosis can more strongly alter the MI- index. Additionally, attention should be paid to the confidence intervals where fewer cases are reported.

The complexity of problems identified here emphasizes the importance of relative survival data for the appropriate analysis of long term results.

As a measurement of the burden of disease, the number of potential life years loss due to premature deaths in a cohort can be calculated (**PYLL**, potential years of life lost, standardized per 100,000 persons or per European standard) as well as the average loss of life years per individual (**AYLL**, average years of life lost). Depending upon the analytic aim (health economy, prevention, health care research) different methods exist for the generation of these measurements. In the results presented here, the age for a premature death is considered to be before 70 years, according to the guidelines of the OECD and the WHO (as seen in the abbreviation PYLL-70 or AYLL-70).

**Shortcuts**

MCR	Munich Cancer Registry (Tumorregister München)
GEKID	Association of Population-based Cancer Registries in Germany (Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.)
SEER	Surveillance, Epidemiology, and End Results (USA)
DCO	Death certificate only
BRD-S	German standard population
ES	European standard population (old)
WS	World standard population
SIR	Standardized incidence ratio
CI	Confidence interval
EAR	Excess absolute risk = excess cancer cases (O - E) per 10,000 person-years
PYLL-70	Potential years of life lost prior to age 70 given a person dies before that age
AYLL-70	Average years of life lost prior to age 70 given a person dies before that age
SMR	Standardized mortality ratio
MI-index	Ratio between mortality and incidence
FRG	Federal Republic of Germany

**Recommended Citation**

Munich Cancer Registry. ICD-10 C37: Thymus cancer - Incidence and Mortality [Internet]. 2018 [updated 2018 Aug 21; cited 2018 Oct 1]. Available from: [https://www.tumorregister-muenchen.de/en/facts/base/bC37\\_\\_E-ICD-10-C37-Thymus-cancer-incidence-and-mortality.pdf](https://www.tumorregister-muenchen.de/en/facts/base/bC37__E-ICD-10-C37-Thymus-cancer-incidence-and-mortality.pdf)

**Copyright**

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

**Disclaimer**

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.